Scientists Discover How Immune Cells Help Pancreatic Cancer Spread Through Blood Vessels
New research reveals how certain immune cells create alternative blood vessels that fuel pancreatic cancer growth and spread.
Summary
Scientists discovered that immune cells called tumor-associated macrophages help pancreatic cancer create its own blood supply through a process called vasculogenic mimicry. These immune cells release tiny packages containing a protein called caveolin-1, which triggers cancer cells to form tube-like structures that act as alternative blood vessels. This discovery led researchers to test a combination therapy targeting both these cancer-made vessels and normal blood vessel growth, showing promising results in laboratory studies.
Detailed Summary
Pancreatic cancer is notoriously aggressive partly because it creates its own blood supply to fuel growth and spread. This study reveals a previously unknown mechanism behind this deadly adaptation.
Researchers used advanced imaging and genetic analysis to study how pancreatic tumors develop alternative blood vessels through vasculogenic mimicry. They discovered that certain immune cells called tumor-associated macrophages actually help cancer cells create these vessel-like structures.
The team found that these immune cells release tiny cellular packages containing caveolin-1 protein. When cancer cells receive these packages, the protein activates a cascade involving DOT1L enzyme and ATG5 gene expression, ultimately enabling cancer cells to form tube-like structures that function as blood vessels. Interestingly, when researchers blocked this process, tumors compensated by increasing normal blood vessel formation.
This led to a breakthrough treatment approach: simultaneously blocking both the cancer's self-made vessels and normal blood vessel growth using existing drugs. The combination therapy showed superior tumor control without significant toxicity in laboratory models. This research matters for longevity because pancreatic cancer has one of the worst survival rates among cancers, with most patients surviving less than a year after diagnosis. Understanding how tumors create their blood supply opens new therapeutic avenues that could significantly extend survival and improve quality of life for patients facing this devastating disease.
Key Findings
- Immune cells help pancreatic cancer create alternative blood vessels through protein packages
- Blocking cancer vessel formation triggers compensatory normal blood vessel growth
- Combination therapy targeting both vessel types shows superior tumor control
- Caveolin-1 protein serves as key messenger between immune cells and cancer cells
Methodology
Researchers used tissue analysis, 3D imaging, genetic sequencing, and laboratory models to study vessel formation. They tested combination drug therapy using DOT1L inhibitor EPZ-5676 and VEGFR inhibitor axitinib in cancer cell cultures and animal models.
Study Limitations
This study was conducted primarily in laboratory settings and animal models. Human clinical trials are needed to confirm safety and effectiveness of the combination therapy approach in pancreatic cancer patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.